- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06131801
Estudo farmacocinético de comprimidos de Venetoclax triturados e dissolvidos em uma solução
Um estudo farmacocinético de comprimidos de Venetoclax triturados e dissolvidos em uma solução em crianças e adultos jovens com doenças hematológicas
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.
Primary Objectives
• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution
Secondary Objectives
- To evaluate the safety of crushed venetoclax tablets administered as an oral solution
- To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors
- To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)
- To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution
Visão geral do estudo
Status
Condições
- Linfoma
- Linfoma Folicular
- Leucemia
- Linfoma de Células B
- Linfoma de Hodgkin
- Linfoma de Burkitt
- AML
- Linfoma Não Hodgkin
- Leucemia Linfocítica Aguda
- Leucemia Mielóide Aguda
- Linfoma Difuso de Grandes Células B
- Malignidade Hematológica
- Leucemia mielóide crônica
- Neoplasia Mieloproliferativa
- Linfoma de células T
- Linfoma Periférico de Células T
- CML
- TODO
- Linfoma cutâneo de células B
Descrição detalhada
Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Site Public Contact
- Número de telefone: (513) 636-2799
- E-mail: cancer@cchmc.org
Locais de estudo
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- Children's Hospital Colorado
-
Investigador principal:
- Kelly Faulk, MD
-
Contato:
- Kelly Faulk, MD
- Número de telefone: 720-777-5771
- E-mail: Kelly.Faulk@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Ainda não está recrutando
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital
-
Contato:
- Himalee Sabnis, MD, MS
- Número de telefone: 57922 404-785-3627
- E-mail: Himalee.sabnis@choa.org
-
Investigador principal:
- Himalee Sabnis, MD, MS
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Recrutamento
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- Children's Hospital of Philadelphia
-
Investigador principal:
- Sarah Tasian, MD
-
Contato:
- Tasleema Patel
- Número de telefone: 917-818-6971
- E-mail: patelt6@chop.edu
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Texas Children's Hospital
-
Contato:
- Michelle Redell, MD
- Número de telefone: 832-822-4242
- E-mail: mlredell@texaschildrens.org
-
Contato:
- Grace Anand
- Número de telefone: 832-824-7705
- E-mail: gxanand@texaschildrens.org
-
Investigador principal:
- Michelle Redell, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Children's Hospital of Wisconsin
-
Investigador principal:
- Zachary Graff, MD
-
Contato:
- Kira Mielke
- E-mail: kmielke@mcw.edu
-
Contato:
- Kara Nelson
- E-mail: knelson@mcw.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
Patients must be <39 years of age at time of study enrollment.
Descrição
Inclusion Criteria:
- Age: Patients must be <39 years of age at time of study enrollment
- Diagnosis: Patients may have a diagnosis of any hematologic malignancy
- Central access: Patients must have an existing venous or arterial access line for PK blood draws
- Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
- Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
- Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.
Exclusion Criteria:
- Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
- Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Children and Young Adults
Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care. |
Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Prazo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Prazo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the time to peak (Tmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Prazo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the apparent terminal phase elimination rate constant (β) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Prazo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the terminal-phase elimination half-life (T1/2) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Prazo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Prazo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: oral clearance (CL/F) of venetoclax |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Prazo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Prazo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the time to peak (Tmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Prazo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the apparent terminal phase elimination rate constant (β) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Prazo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the terminal-phase elimination half-life (T1/2) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Prazo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Prazo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: oral clearance (CL/F) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias por local
- Neoplasias
- Doença crônica
- Atributos da doença
- Doenças do sistema imunológico
- Infecções
- Doenças Virais
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Infecções por vírus de DNA
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Leucemia Mieloide
- Doenças da Medula Óssea
- Leucemia Linfóide
- Infecções pelo vírus Epstein-Barr
- Infecções Herpesviridae
- Infecções por Vírus Tumorais
- Condições Patológicas, Sinais e Sintomas
- Doenças hemic e linfáticas
- Leucemia
- Leucemia Mieloide Aguda
- Neoplasias Hematológicas
- Linfoma
- Linfoma de Células B
- Linfoma de Células B Grandes Difuso
- Leucemia-Linfoma Linfoblástico de Células Precursoras
- Linfoma de Burkitt
- Linfoma Não-Hodgkin
- Linfoma Folicular
- Distúrbios mieloproliferativos
- Doença de Hodgkin
- Linfoma de Células T
- Linfoma de Células T Periférico
- Leucemia Mielóide, Crônica, BCR-ABL Positivo
Outros números de identificação do estudo
- Venetoclax PK
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .